ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

fidelity
2025.11.12 12:15
portai
I'm PortAI, I can summarize articles.

ImageneBio reported its Q3 2025 financial results, highlighting $142.6 million in cash and equivalents. The company announced a protocol amendment for its Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis to optimize study design. The leadership team was strengthened with new appointments, including Dr. Kristin Yarema as CEO. Upcoming presentations at the Inflammatory Skin Disease Summit will showcase novel data on IMG-007's efficacy in alopecia areata and atopic dermatitis. Topline data from the ongoing trial is expected in 2027.

Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.